At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 153 enrolled
Drug / intervention
Ecopipam +1 moredrug
Likely dose
Ecopipam 2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam in Children and Adolescents With Tourette's Syndrome
In Brief
A Phase 2 clinical trial evaluating Ecopipam and Placebo for Tourette Syndrome. Completed, enrolled 153 participants across 70 sites in 5 countries.
Detailed Summary
This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching placebo tablets
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTourette Syndrome
CountriesCanada, France, Germany, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
First PostedJul 2019
Primary CompletionSep 2021
TodayJul 2026
First PostedJul 5, 2019
Enrollment StartJun 28, 2019
Primary CompletionSep 23, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 7.0 years ago
Interventions
Ecopipamdrug
Ecopipam HCI tablets administered PO to establish 2 mg/kg/day
Placebodrug
Matching Placebo